Albireo Pharma, Inc. (NASDAQ:ALBO) – Investment analysts at Wedbush issued their FY2022 earnings estimates for Albireo Pharma in a research report issued to clients and investors on Wednesday. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings per share of $7.44 for the year. Wedbush currently has a “Buy” rating on the stock.

ALBO has been the subject of a number of other reports. Needham & Company LLC reissued a “buy” rating on shares of Albireo Pharma in a research note on Thursday, October 26th. ValuEngine lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Zacks Investment Research lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 13th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Friday, November 17th. Finally, Roth Capital assumed coverage on shares of Albireo Pharma in a research note on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Albireo Pharma has an average rating of “Buy” and a consensus target price of $53.75.

Albireo Pharma (NASDAQ:ALBO) opened at $29.80 on Friday. Albireo Pharma has a 1 year low of $15.31 and a 1 year high of $30.50.

In related news, major shareholder Plc Astrazeneca sold 500,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $21.40, for a total value of $10,700,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 22.30% of the stock is owned by corporate insiders.

WARNING: “Albireo Pharma, Inc. (ALBO) Expected to Post FY2022 Earnings of $7.44 Per Share” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/albireo-pharma-inc-albo-expected-to-post-fy2022-earnings-of-7-44-per-share/1797263.html.

Albireo Pharma Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.